Cannabidiol (CBD) is a cannabinoid found in #$%$. It is a major constituent of the plant, representing up to 40% in its extracts. Compared to THC, cannabidiol is non-psychoactive, and is considered to have a wider scope of medical applications than THC, including to epilepsy, multiple sclerosis spasms, anxiety disorders, schizophrenia, and nausea.
Cannabidiol has displayed sedative effects in animal tests. Some research, however, indicates that CBD can increase alertness. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver.
Medically, it has been shown to relieve convulsion, inflammation, anxiety, and nausea, as well as inhibit cancer cell growth. Recent studies have shown cannabidiol to be as effective as atypical antipsychotics in treating schizophrenia. Studies have also shown that it may relieve symptoms of dystonia.
In November 2007, it was reported that CBD reduces growth of aggressive human breast cancer cells in vitro and reduces their invasiveness.
A 2008 study published in the British Journal of Psychiatry showed significant differences in the Oxford-Liverpool Inventory of Feelings and Experiences scores between three groups: the first consisted of non-#$%$ users, the second consisted of users with THC detected, and the third consisted of users with both THC and CBD detected. The THC-only group scored significantly higher for unusual experiences than the THC-and-CBD group, whereas the THC-and-CBD group had significantly lower introvertive anhedonia scores than the THC-only group and the non-#$%$ user group. This research indicates that CBD acts as an anti-psychotic and may counteract the potential psychotomimetic effects of THC on individuals with latent schizophrenia.
you know gambler let them pump the cause that is one thing that should be told .everybody knows it has nothing to do with the fact that mjna is still trending lower despite the mj pumps on the board,some is very good info should be shared pro or against mjna.
Study on Medical Benefits of CBD Gives #$%$ Industry, MMJ Companies More Credibility
Tags: cannabidiol, #$%$ science, cbd, dixie elixirs
In the battle for credibility between medical #$%$ supporters and MMJ opponents, chalk one up for the marijuana industry.
A new study spearheaded by the California Pacific Medical Center found strong evidence that cannabidiol (or CBD) – a key compound in marijuana – is effective in fighting some types of cancer.
The findings will provide a particularly big boost to companies that make cannabidiol-based products, such as Dixie Elixirs & Edibles, which is seeing widespread interest for a new line of hemp-based CBD tinctures, topicals and capsules. Cannabidiol offers some of the pain-relieving benefits of THC – without the “high.” Some observers see CBD as the next big thing in the medical #$%$ industry, saying the potential market is huge. Here’s the main reason why: Hemp-based CBD products are legal in the United States, so you don’t need to live in a state with medical #$%$ laws or hold an MMJ card to buy and use them. Dixie Elixirs and other companies are now hoping to capitalize on that by expanding nationally and even into other countries.
In the spring of 1998, the British government licensed a company called GW Pharmaceuticals to grow #$%$ and develop a precisely consistent plant extract for use in clinical trials. GW's co-founder Geoffrey Guy, MD, was convinced —and had convinced the Home Office— that by using CBD-rich plants, GW could produce a #$%$-based medicine with little or no psychoactive effect. That summer Guy described his approach at a meetingof the International Cannabinoid Research Society. In addition to countering the psychoactivity of THC, Guy said, CBD conferred benefits of its own. Queen Victoria had used CBD-rich #$%$ for menstrual cramps. Indeed, animal studies suggest that CBD lessened anxiety and reduced the severity and frequency of seizures.
It was assumed that generations of breeding for maximum THC had reduced CBD in California #$%$ to trace levels. GW had gotten its CBD-rich strains by acquiring the genetic library of HortaPharm, a Dutch seed company run by American ex-pat naturalists, David Watson and Robert Clarke. Tod Mikuriya, MD, founder of the Society of #$%$ Clinicians, expressed hope that "our Burbanks in the hills" would have preserved or could develop CBD-rich strains if and when an analytic test lab began serving the medical #$%$ industry.
As the years went by, more and more promising studies involving CBD were described at meetings of the ICRS, the International Association for Cannabinoid Medicine
Cannabidiol —CBD— is a compound in #$%$ that has medical effects but does not make people feel “stoned” and actually counters some of the effects of THC. After decades in which only high-THC #$%$ was available, CBD-rich strains are now being grown by and for medical users.
The reduced psychoactivity of CBD-rich #$%$ may make it an appealing treatment option for patients seeking anti-inflammatory, anti-pain, anti-anxiety and/or anti-spasm effects without disconcerting euphoria or lethargy.
Scientific and clinical studies indicate that CBD could be effective in easing symptoms of a wide range of difficult-to-control conditions, including: rheumatoid arthritis, diabetes, alcoholism, PTSD, epilepsy, antibiotic-resistant infections and neurological disorders. CBD has demonstrated neuroprotective effects, and its anti-cancer potential is currently being explored at several academic research centers in the U.S. and other countries.
Beyond THC: Cannabidiol and the Future of #$%$
Martin A. Lee, Author, Smoke Signals
Cannabidiol (CBD), a nonpsychoactive component of marijuana, has extraordinary therapeutic qualities, claims Lee. Discover the various molecular mechanisms through with CBD exerts its effects as an anticonvulsant, antipsychotic and neuro-protective compound. This lecture will also address recent efforts to reintroduce CBD-rich remedies and how the #$%$ industry has responded to the rediscovery of CBD, which doesn’t make people feel high and can actually counter the psychoactive effects of THC.
Corticobasal degeneration (CBD) is a neurodegenerative brain disease that has no known cause, treatment or cure. It affects nerve cells that control walking, balance, mobility, vision, speech, and swallowing.
CBD is rare, affecting an estimated 2000-3000 people in United States, of whom only 500-750 are diagnosed.
Symptoms begin, on average, when an individual is in the early 60's, but may start as early as in the 40's. These include:
Stiffness, shakiness, jerkiness, slowness, and clumsiness in either the upper or lower extremities
Difficulty with speech generation (dysphasia)
Difficulty with articulation (dysarthria)
Difficulty controlling the muscles of the face and mouth
Walking and balance difficulty
Asymmetric onset of symptoms (occuring on one side of the body first then gradually moving to the other side)
Memory or behavior problems